Epstein Secrets

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug

nt on the upcoming election, with discussion on voter turnout and how national security will play a 'key role' in the election, with Democratic Rep. Karen Bass, Voto Latino CEO and President Maria Teresa Kumar, and former National Security Advisor Lt. Gen. (Ret.) Henry McMaster; 3:30 PM • Armenian foreign

63> (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average — in a large study led by the U.S. National Institutes of Health." The drug

nt on the upcoming election, with discussion on voter turnout and how national security will play a `key role' in the election, with Democratic Rep. Karen Bass, Voto Latino CEO and President Maria Teresa Kumar, and former National Security Advisor Lt. Gen. (Ret.) Henry McMaster; 3:30 PM * Armenian foreign

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug

nt on the upcoming election, with discussion on voter turnout and how national security will play a 'key role' in the election, with Democratic Rep. Karen Bass, Voto Latino CEO and President Maria Teresa Kumar, and former National Security Advisor Lt. Gen. (Ret.) Henry McMaster; 3:30 PM • Armenian foreign